SCHEMBL5485508

SCHEMBL5485508

COc1ccc2c(c1)NC(=O)C2(c1ccc(O)cc1)c1ccc(O)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.57
ADORA3 P0DMS8 1/20 0.57
KCNH2 Q12809 1/20 0.57
MAPT P10636 2/20 0.49
CNR1 P21554 1/20 0.46
HTT P42858 1/20 0.46
GPR35 Q9HC97 1/20 0.46
GPR55 Q9Y2T6 1/20 0.46
AKR1B1 P15121 1/20 0.44
LMNA P02545 3/20 0.44
MEN1 O00255 1/20 0.44
XBP1 P17861 1/20 0.44
KMT2A Q03164 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
PDE7A Q13946 1/20 0.43
ADAM17 P78536 1/20 0.42
OTUD7B Q6GQQ9 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
LTA4H P09960 1/20 0.39
ESR2 Q92731 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5478595 0.89 CHRM2 (0.57) CHRM2ADORA3KCNH2MAPTCNR1
SCHEMBL3198592 0.84 CHRM2 (0.78) CHRM2ADORA3KCNH2MAPTCNR1
SCHEMBL11753047 0.83 CHRM2 (0.51) CHRM2ADORA3KCNH2MAPTCNR1
SCHEMBL5483580 0.81 CHRM2 (0.62) CHRM2ADORA3KCNH2MAPTCNR1
SCHEMBL11753042 0.80 CHRM2 (0.48) CHRM2ADORA3KCNH2MAPTCNR1
SCHEMBL6624390 0.80 PGR (0.47) CHRM2ADORA3KCNH2MAPTCNR1
SCHEMBL5485363 0.78 CHRM2 (0.62) CHRM2ADORA3KCNH2MAPTCNR1
SCHEMBL17813120 0.76 MAPT (0.69) CHRM2ADORA3KCNH2MAPTLMNA
SCHEMBL25502467 0.75 CHRM2 (0.82) CHRM2ADORA3KCNH2MAPTCNR1
SCHEMBL5483069 0.75 CNR1 (0.60) CHRM2ADORA3KCNH2MAPTCNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US claimed
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US disclosed
EP-1734951-A2 DIPHENYL-INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TopoTarget A/S (DK) 2006-12-27 EP disclosed
WO-2005097107-A2 DIPHENYL - INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TOPOTARGET A/S (DK) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer MTOR, RICTOR, CDK4 CHRM2 2994/4885ADORA3 3566/4885KCNH2 4593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.